EGFR and non-small cell lung carcinoma: To address this gap, we devised an indirect comparison using 1st-G TKIs as a bridge to compare the efficacy and safety of 1st-G TKIs + chemo versus 3rd-G TKIs in treating patients with advanced NSCLC harboring EGFR mutations.